West Paces Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

West Paces Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-613	Closed	-$37.9K	–	568
2022 Q3	$37.9K	Buy	613 +192	+46%	+$13.4K	0.01%	226
2022 Q2	$33.6K	Buy	421 +185	+78%	+$17.5K	0.01%	251
2022 Q1	$24.8K	Hold	236	–	–	0.01%	291
2021 Q4	$25.4K	Buy	236 +23	+11%	+$2.51K	0.01%	285
2021 Q3	$23.3K	Hold	213	–	–	0.01%	272
2021 Q2	$19.9K	Buy	+213	New	+$19.6K	0.01%	292

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

West Paces Advisors's HZNP Position: Q4 2022 in Review

West Paces Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 613 shares — an estimated $37.9K sold.

West Paces Advisors first reported a position in HZNP in Q2 2021 and held it in 6 quarters. The position peaked at $37.9K in Q3 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

West Paces Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
West Paces Advisors sold 613 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $37.9K.
West Paces Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 6 quarters.
West Paces Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $37.9K in Q3 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on West Paces Advisors's 13F filing for Q4 2022, filed 18 Dec 2023.